Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00041093
Other study ID # GOG-0127S
Secondary ID NCI-2012-02476CD
Status Completed
Phase Phase 2
First received July 8, 2002
Last updated January 9, 2018
Start date June 2002

Study information

Verified date January 2018
Source Gynecologic Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase II trial to study the effectiveness of docetaxel in treating patients who have persistent or recurrent cervical cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.


Description:

PRIMARY OBJECTIVES:

I. Determine the antitumor activity of docetaxel in patients with persistent or recurrent squamous cell carcinoma of the cervix.

II. Determine the toxicity of this drug in these patients.

OUTLINE: This is a multicenter study.

Patients receive docetaxel IV over 1 hour on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date
Est. primary completion date October 23, 2006
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- Histologically confirmed persistent or recurrent squamous cell carcinoma of the cervix

- Progressive disease

- At least 1 unidimensionally measurable target lesion

- At least 20 mm by conventional techniques

- At least 10 mm by spiral CT scan

- Tumors within a previously irradiated field are not considered target lesions

- One prior systemic chemotherapeutic regimen for advanced, metastatic, or recurrent squamous cell carcinoma of the cervix required

- Chemotherapy administered as a radiosensitizer in conjunction with primary radiotherapy is not considered a systemic chemotherapy regimen

- Ineligible for a higher priority GOG protocol (e.g., any active Phase III GOG protocol or GOG-0076)

- Performance status - GOG 0-2

- Absolute neutrophil count at least 1,500/mm3

- Platelet count at least 100,000/mm3

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- SGOT no greater than 2.5 times ULN

- Alkaline phosphatase no greater than 2.5 times ULN

- Creatinine no greater than 1.5 times ULN

- No congestive heart failure

- No unstable angina, myocardial infarction, or new cardiac arrhythmia within the past 6 months

- Negative pregnancy test

- Fertile patients must use effective contraception

- No active infection requiring antibiotics

- No greater than grade 1 sensory and motor neuropathy

- No other invasive malignancy within the past 5 years except nonmelanoma skin cancer

- At least 3 weeks since prior biologic or immunologic therapy directed at malignant tumor

- One prior noncytotoxic regimen (e.g., monoclonal antibodies, cytokines, or small-molecule signal transduction inhibitors) for recurrent or persistent disease allowed

- Recovered from prior chemotherapy

- No prior docetaxel

- No more than 1 prior cytotoxic chemotherapy regimen

- At least one week since prior hormonal therapy directed at malignant tumor

- Concurrent hormone replacement therapy allowed

- Recovered from prior radiotherapy

- Recovered from recent prior surgery

- At least 3 weeks since any prior therapy directed at malignant tumor

- No prior anticancer therapy that would preclude study

- No concurrent amifostine or other protective agents

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Docetaxel
Given IV

Locations

Country Name City State
United States Gynecologic Oncology Group Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Gynecologic Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Duration of progression-free interval 5 years
Primary Frequency and duration of objective response as assessed on radiologic scan 5 years
Primary Frequency and severity of observed adverse effects 5 years
Primary Survival time 5 years
See also
  Status Clinical Trial Phase
Recruiting NCT03968406 - Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers Phase 1
Active, not recruiting NCT03508570 - Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Phase 1
Completed NCT00309959 - ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Recruiting NCT04574635 - Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT03439085 - DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers Phase 2
Recruiting NCT03987555 - Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Terminated NCT03345784 - Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers Phase 1
Completed NCT01266460 - Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2
Completed NCT00064077 - Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Phase 3
Active, not recruiting NCT02257528 - Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer Phase 2
Recruiting NCT05310331 - Donafenib for Recurrent Cervical Cancer Phase 2
Recruiting NCT05310383 - Tislelizumab and Radiotherapy for Recurrent Cervical Cancer Phase 2
Recruiting NCT05310305 - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Completed NCT01281852 - Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer Phase 1
Recruiting NCT05290935 - Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial Phase 2
Recruiting NCT06238635 - Dostarlimab and Cobolimab in Advanced Cervical Cancer Phase 2
Completed NCT02921269 - Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer Phase 2
Recruiting NCT06157151 - PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer Phase 2
Completed NCT00499031 - Cetuximab in Treating Patients With Persistent or Recurrent Cervical Cancer Phase 2